| Company Name: | Omrix Biopharmaceuticals, Incorporated | | Ticker Symbol: | OMRI | | | WWW Address: | www.omrix.com | | CEO: | Robert Taub | | No. of Employees: | 212 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company that develops, manufactures and markets innovative biological products for the biosurgical and immunotherapy markets.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 24.99 |  0.0 | - | - | 0 | 25.02 | 24.98 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 428.1 | 17.1 | 1.00 | 0.69 | 0.00 | 36.2 | 0.0 | 36.30 - 8.99 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 24.99 | $ | | PE Ratio - LTM | 36.2 | |
| Market Capitalisation | 428.1 | mil |
| Latest Shares Outstanding | 17.1 | mil |
| Earnings pS (EPS) | 0.69 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 291,061 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 14.0 | mil |
| Float as % of Shares Outstanding | 81.6 | % |
| Foreign Sales | 37 | mil |
| Domestic Sales | 24 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 22.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 8.30 | % |
| Gross Profit Margin | 43.4 | % |
| EBITDA Margin | 12.2 | % |
| Pre-Tax Profit Margin | 16.2 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 7.7 | % |
| Return on Equity (ROE) | 9.3 | % |
| Return on Capital Invested (ROCI) | 9.3 | % |
| Current Ratio | 7.6 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 62.8 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 6.48 | $ |
| Cash pS | 2.76 | $ |
| Book-Value pS | 7.54 | $ |
| Tangible Book-Value pS | 7.54 | $ |
| Cash Flow pS | 0.77 | $ |
| Free Cash Flow pS | -0.29 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.31 | |
| Price/Tangible Book Ratio | 3.31 | |
| Price/Cash Flow | 32.5 | |
| Price/Free Cash Flow | -86.2 | |
| P/E as % of Industry Group | 366.0 | % |
| P/E as % of Sector Segment | 823.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 97 | 4,981 | 3,819 |
| 4 Weeks | 25.04 | 24.81 | 24.92 | 0.3 | 97 | 6,746 | 114,688 |
| 13 Weeks | 25.04 | 8.99 | 19.50 | 28.2 | 156 | 6,356 | 387,698 |
| 26 Weeks | 25.04 | 8.99 | 16.76 | 49.1 | 208 | 4,142 | 517,775 |
| 52 Weeks | 36.30 | 8.99 | 33.87 | -26.2 | 115 | 3,877 | 969,306 |
| YTD | 36.30 | 8.99 | - | -28.1 | 117 | 3,856 | 975,521 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 24.98 | 24.97 | 20.71 | 19.29 | 18.27 | 1.00 | 0.95 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 40.54 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 55.23 |
| R&D | 0.00 | NA | 23.16 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 41.3 | 34.3 | -3.2 |
| Earnings % | 0.5 | -3.1 | -48.2 |
| EPS % | 0.0 | 0.0 | -58.2 |
| EPS $ | 0.00 | 0.00 | -0.96 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 75.98 |
| Current Ratio | 8.0 |
| Quick Ratio (Acid Test) | 6.6 |
| Liquidity Ratio (Cash) | 5.15 |
| Receivables Turnover | 3.7 |
| Average Collection Period | 97 |
| Working Capital/Equity | 93.1 |
| Working Capital pS | 6.50 |
| Cash-Flow pS | 0.78 |
| Free Cash-Flow pS | -0.47 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 11.33 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 18.4 |
| Total Debt/Equity (Gearing Ratio) | 0.01 |
| LT Debt/Equity | 0.01 |
| LT Debt/Capital Invested | 9.2 |
| LT Debt/Total Liabilities | 2.9 |
| Interest Cover | 59.0 |
| Interest/Capital Invested | 0.16 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.82 |
| Tobin's Q Ratio | 2.95 |
| Current P/E Ratio - LTM | 36.20 |
| Enterprise Value (EV)/EBITDA | 51.90 |
| Enterprise Value (EV)/Free Cash Flow | -51.31 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.31 |
| Price/Book Ratio - LTM | 3.31 |
| Price/Cash Flow Ratio | 32.5 |
| Price/Free Cash Flow Ratio - LTM | -86.2 |
| Price/Sales Ratio | 5.44 |
| P/E Ratio (1 month ago) - LTM | 36.1 |
| P/E Ratio (26 weeks ago) - LTM | 27.5 |
| P/E Ratio (52 weeks ago) - LTM | 36.8 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 366.0 |
| P/E as % of Sector Segment | 823.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 36.2 |
| PER SHARE FIGURES |
| LT Debt pS | 0.05 |
| Current Liabilities pS | 0.92 |
| Tangible Book Value pS - LTM | 7.54 |
| Book Value pS - LTM | 7.54 |
| Capital Invested pS | 6.97 |
| Cash pS - LTM | 2.76 |
| Cash Flow pS - LTM | 0.77 |
| Free Cash Flow pS - LTM | -0.29 |
| Earnings pS (EPS) | 0.69 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -12.91 |
| Free Cash Flow Margin 5YEAR AVG | -5.07 |
| Net Profit Margin | 19.4 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.52 |
| Return on Equity (ROE) | 10.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.52 |
| Return on Capital Invested (ROCI) | 10.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 8.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 43.4 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 12.2 |
| EBIT Margin - LTM | 16.4 |
| Pre-Tax Profit Margin | 19.4 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 322 |
| Revenue per Employee | 291,061 |
| Net Income per Employee | 56,321 |
| Average Collection Period | 134 |
| Receivables Turnover | 3.7 |
| Day's Inventory Turnover Ratio | 188 |
| Inventory Turnover | 1.9 |
| Inventory/Sales | 33.2 |
| Accounts Payble/Sales | 12.10 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 0.56 |
| Fixed Assets Turnover | 3.21 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 2.38 |
| Revenue per $ Plant | 4.14 |
| Revenue per $ Common Equity | 0.52 |
| Revenue per $ Capital Invested | 0.52 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 22.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 7.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.3 |
|
|  
|
| |
 |  |